<DOC>
	<DOCNO>NCT00557466</DOCNO>
	<brief_summary>This study evaluate dose response relationship among four dos indacaterol well placebo deliver via TWISTHALER® device .</brief_summary>
	<brief_title>A Dose Ranging Trial 4 Doses Indacaterol Delivered Via TWISTHALER® Device Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Male female adult age ≥ 40 year , sign Informed Consent Form prior initiation studyrelated procedure ( include adjustment current COPD treatment ) Cooperative outpatient diagnosis COPD ( moderate severe classify Global Initiative Obstructive Lung Disease ( GOLD ) Guidelines , 2006 ) : Smoking history least 10 pack year Postbronchodilator Forced Expiratory Volume one second ( FEV1 ) &lt; 80 % ≥30 % predict normal value . Postbronchodilator FEV1/Forced vital capacity ( FVC ) &lt; 70 % Pregnant woman , nurse mother , female childbearing potential , regardless whether sexually active , use acceptable method contraception . Patients hospitalized exacerbation airway disease within 6 week prior Visit 1 Visit 1 Visit 2 . Patients history asthma . Patients acute respiratory tract infection within 4 week prior Visit 1 , allow enter study . Other clinically significant condition may interfere study conduct patient safety specify protocol . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>QMF</keyword>
	<keyword>indacaterol</keyword>
	<keyword>TWISTHALER® device</keyword>
</DOC>